Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$8.33 USD
-0.15 (-1.77%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $8.34 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FOLD 8.33 -0.15(-1.77%)
Will FOLD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for FOLD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FOLD
Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength?
Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy?
FOLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect?
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates
Other News for FOLD
Interesting FOLD Put And Call Options For November 21st
Pocket Pivot appears for FOLD after 6.4% move
Amicus Therapeutics (FOLD) Upgraded by Needham with Increasing Sales Potential
Amicus upgraded to Buy at Needham banking on kidney disease therapy
Target initiated, Nike upgraded: Wall Street’s top analyst calls